Thursday, 2 March, 2017

14:00-18:00  Registration

18:00-19:00  Get-Together Reception  Exhibition Area

Friday, 3 March, 2017

07:30  Registration

09:00-09:15  Opening Ceremony:  Hall A

Greetings by:
Prof. Talma Rosenthal, Israel, Honorary Chairman
Prof. Giuseppe Mancia, Italy, Honorary Chairman
Prof. Reuven Zimlichman, Israel, Chairman

09:15-10:30  Plenary Session 1: Fixed Combination and Cardiovascular Disease  Hall A

Chairs: Hermann Haller, Germany; Alberto Zanchetti, Italy

09:15  Long Term Advantages of Initial Combination Treatment: New Evidence
Giuseppe Mancia, Emeritus Professor of Medicine, University Milano-Bicocca, Milano, Italy

09:40  Combination Therapy in the Cardiometabolic Syndrome
Reuven Zimlichman, Sackler Faculty of Medicine, Tel Aviv University, The E. Wolfson Medical Center, Holon, Israel

10:05  Can a Polypill, One Single Tablet, Combat Different Cardiovascular Risk Factors?
Talma Rosenthal, Sackler Faculty of Medicine, Tel Aviv University, Israel

10:30-11:00  Coffee Break, Exhibition Visit and Posters Viewing

11:00-12:20  Plenary Session 2: Hypertension and Combination Therapy  Hall A

Chairs: Giuseppe Mancia, Italy; Reuven Zimlichman, Israel

11:00  Benefits and Burdens of Antihypertensive Treatment: Meta-Analyses of Randomized Controlled Trials
Alberto Zanchetti, Emeritus Professor of Internal Medicine at the University of Milan, Italy

11:25  Inhibition of SGLT-2 and Antihypertensive Treatment Strategies: New Mechanisms of Cardiovascular Protection
Hermann Haller, Dept. of Nephrology and Hypertension Medicine, University of Hannover, Hannover Medical School, Germany

11:50  Vascular Biology of Hypertension: Clinical Implications
Rhian M. Touyz, Institute of Cardiovascular Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, UK

12:15  Discussion

12:30-13:30  Lunch Break, Exhibition Visit and Posters Viewing
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Chairs</th>
<th>Venue</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30-15:30</td>
<td>Plenary Session 3: Hypertension and Metabolic Syndrome</td>
<td>Chairs: Rhian M. Touyz, UK; Reuven Zimlichman, Israel</td>
<td>Hall A</td>
</tr>
<tr>
<td>13:30</td>
<td>Arterial Destiffening in Hypertensive Patients with Type 2 Diabetes</td>
<td>Stephane Laurent, Dept. of Clinical Pharmacology in the Hôpital Européen Georges Pompidou, France</td>
<td></td>
</tr>
<tr>
<td>13:55</td>
<td>Metabolic Syndrome: Does it Exist?</td>
<td>Dimitri Mikhailidis, University College London, UK</td>
<td></td>
</tr>
<tr>
<td>14:20</td>
<td>Target BP in the Elderly and use of Combination Treatment</td>
<td>Enrico Agabiti-Rosell, Dept. of Clinical and Experimental Sciences, University of Brescia, Brescia Medical School, Italy</td>
<td></td>
</tr>
<tr>
<td>14:45</td>
<td>From Epidemiological Transition to Modern Cardiovascular Epidemiology: Hypertension in the 21st Century</td>
<td>Jacques Blacher, Hypertension and cardiovascular prevention unit, Hôtel-Dieu university Hospital, Assistance Publique-Hôpitaux de Paris, University Paris Descartes, Paris, France</td>
<td></td>
</tr>
<tr>
<td>15:10</td>
<td>Correct Combinations of Antihypertensive Drugs According to the Principles of Clinical Pharmacology</td>
<td>Stefano Taddei, Dept. of Clinical and Experimental Medicine, University of Pisa, Italy</td>
<td></td>
</tr>
<tr>
<td>15:30-16:00</td>
<td>Coffee Break, Exhibition Visit and Posters Viewing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00-17:00</td>
<td>Plenary Session 4: The Kidney and Vascular Disease</td>
<td>Chairs: Stephane Laurent, France; Dimitri Mikhailidis, UK</td>
<td>Hall A</td>
</tr>
<tr>
<td>16:00</td>
<td>Combination Antihypertensive Therapy in Chronic Kidney Disease: Does SPRINT tell us the Truth?</td>
<td>Alexander Kirsch, Medical University Graz, Department of Internal Medicine, Clinical Division of Nephrology, Graz, Austria</td>
<td></td>
</tr>
<tr>
<td>16:20</td>
<td>Which Combination Therapy in the Renal Patient?</td>
<td>Jean-Michel Halimi, Service de Néphrologie, CHU Tours, 2 Bd Tonnellé, 37044 Tours, France</td>
<td></td>
</tr>
<tr>
<td>16:40</td>
<td>Total Cardiovascular Risk Evaluation and Management in patients with PAD</td>
<td>Marianne Brodmann, Dept. of Internal Medicine, Medical University Graz, Austria</td>
<td></td>
</tr>
<tr>
<td><strong>Saturday, 4 March, 2016</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:30</td>
<td>Registration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:45-10:00</td>
<td>Plenary 5: Heart Failure and Hemodynamics</td>
<td>Chairs: Marianne Brodmann, Austria; Jean-Michel Halimi, France</td>
<td>Hall A</td>
</tr>
<tr>
<td>08:45</td>
<td>Need for Pleitropic Therapy in Chronic Heart Failure</td>
<td>Dirk L. Brutsaert, Professor Emeritus, University of Antwerp, Antwerp, Belgium</td>
<td></td>
</tr>
<tr>
<td>09:10</td>
<td>Optimal Treatment of Heart Failure: Is there a Place of Combination Therapy?</td>
<td>Amitai Elkayam, Assuta Medical Center, Tel Aviv, Israel</td>
<td></td>
</tr>
<tr>
<td>09:35</td>
<td>Cross-Talk between Microcirculation and Macrocirculation: Effects of Combination Treatment</td>
<td>Damiano Rizzoni, Dept. of Medical and Surgical Sciences, University of Brescia, Italy</td>
<td></td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>Coffee Break, Exhibition Visit and Posters Viewing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30-11:10</td>
<td>Plenary Session 6: Lipids and Combination Therapy</td>
<td>Chairs: Dirk L. Brutsaert, Belgium; Amitai Elkayam, Israel</td>
<td>Hall A</td>
</tr>
<tr>
<td>10:30</td>
<td>PCSK9: Together or Alone? Current State of Knowledge 2017</td>
<td>Maciej Banach, Dept. of Hypertension, Medical University of Lodz, Poland</td>
<td></td>
</tr>
<tr>
<td>10:50</td>
<td>Advance towards Personalized Treatment for Prevention of Atherosclerotic Cardiovascular Disease: Genetics Proteomics Immunology and Optimal Choice of Treatment, the Future is here</td>
<td>Dov Gavish, Medicine A Wolfson, Sackler Faculty of Medicine Tel Aviv University, Israel</td>
<td></td>
</tr>
</tbody>
</table>
11:10-12:25  Plenary Session 7: Free Communications  
Chairs: Damiano Rizzoni, Italy; Talma Rosenthal, Israel

11:10  Use of Polypill Components among a Swiss Population-Based Study  
Julien Castioni, Dept. of Medicine, Internal Medicine, Lausanne University Hospital, Switzerland

11:25  Fixed Dose Combination Olmesartan/Amlodipine Decreases Blood Pressure and Improves Ventricular-Arterial Coupling  
Iana Simova, Dept. of Cardiology, Acibadem City Clinic - University Hospital, Bulgaria

11:40  Anti hypertensive Efficacy and Uric Acid Lowering Effect of the Combination of Losartan Hydrochlorothiazide and Amlodipine Compared with a Combination of Bisoprolol Hydrochlorothiazide and Amlodipine  
Olena Torbas, Symptomatic Hypertension, FI NSC Institute of Cardiology n.a. M.D.Strazhesko, Ukraine

11:55  A Cross Sectional Study of Metformin Induced Vitamin B12 Deficiency in Metabolic Syndrome Patients among North Indian Rural Population  
Hariharan Munganda, Internal Medicine and Endocrinology, Asian Institute of Medical Sciences, India

12:10  Rosuvastatin/Olmesartan FDC for the Treatment of CAD  
Vuong Trieu, Clinical Research, Stocosil, USA

12:30-13:30  Lunch Break, Exhibition Visit and Posters Viewing

13:30-15:30  Plenary Session 8: Diabetes and Combination Therapy  
Chairs: Maciej Banach, Poland; Bernard I. Levy, France

13:30  Outcomes of iGlarLixi, a Titratable Fixed-ratio Combination of Insulin Glargine/Lixisenatide, versus Insulin Glargine and Lixisenatide by Baseline Characteristics: LixiLan-O Trial  
Bruno Guerci, University of Lorraine and Brabois Adult Hospital, Vandœuvre-lès-Nancy, France

13:50  Fixed Dose Combinations with Empagliflozin  
Eberhard Standi, Munich Diabetes Research Group e.V. at Helmholtz Centre, Munich, Germany

14:10  Arguments for Early Fixed-Dose Glucose Lowering Combination Therapies  
Guntram Schernthaner, Dept. of Medicine I, Rudolstiftung Hospital, Vienna, Austria

14:30  Why and How do We Have to Use Drugs Combinations for Treatment of Hypertensive Patients  
Bernard I. Levy, Emeritus Professor of Physiology, France

14:50  New Opportunities from GLP-1 RA Combination Therapies in Type 2 Diabetes  
Francesco Giorgino, University of Bari Aldo Moro, Bari, Italy

15:10  Discussion

15:30-16:00  Coffee Break, Exhibition Visit and Posters Viewing

16:00-16:50  Plenary Session 9: Therapy and Hypertension Therapy  
Chairs: Guntram Schernthaner, Austria; Dov Gavish, Israel

16:00  Novel Combination Therapy in Hypertension: Chlorthalidone with Spironolactone  
Uday JadHAV, Dept. of Cardiology, MGM New Bombay Hospital, Vashi, India

16:25  HOPE-3: Efficacy and Safety of Combined BP and Lipid Lowering for Primary Prevention of Cardiovascular Disease  
Basil S. Lewis, Lady Davis Carmel Medical Center, The Ruth and Bruce Rappaport School of Medicine of the Technion, Haifa, Israel
Sunday, 5 March, 2017

08:00 Registration

08:30-10:00 Plenary Session 10: Combination and Cardiovascular Disease
Hall A
Chairs: Flávio D. Fuchs, Brazil; Bojan Jelakovic, Croatia

08:30 Cardiovascular Outcome Trials in Diabetes: Cardiologist's Point of View
Francesco Cosentino, Cardiology Unit, Dept. of Medicine, Karolinska University Hospital, Solna, Sweden

08:55 Combination Therapy in the Management of Stable Coronary Artery Disease in the PCI Era
Giuseppe Ambrosio, Dept. of Cardiology, University of Perugia School of Medicine, Perugia, Italy

09:20 What is the Optimal Two-Drug and Three-Drug Fixed Combination?
Andrzej Januszewicz, Dept. of Hypertension, Institute of Cardiology, Warsaw, Poland

09:35 Comparison of the Effects of Zofenopril or Ramipril Plus Acetylsalicylic Acid in Post-Myocardial Infarction Patients with Left Ventricular Systolic Dysfunction
Salvatore Novo, Dept. of Internal Medicine and Cardiovascular Disease, University of Palermo, Italy

10:00-10:30 Coffee Break, Exhibition Visit and Posters Viewing

10:30-12:30 Closing Plenary Session 11: Combination Therapy
Hall A
Chairs: Talma Rosenthal, Israel; Reuven Zimlichman, Israel

10:30 Amiloride, an Obligatory Companion of Chlorthalidone and other Diuretics
Flávio D. Fuchs, Hospital de Clinicas de Porto Alegre, Brazil

10:55 Combination Therapy and Kidney Outcome-What should be the Target?
Bojan Jelakovic, University of Zagreb School of Medicine, University Hospital Center Zagreb, Croatia

11:20 The Role of Combination Therapy to Lipid Targets: Is Getting to Target Levels enough or do the Means to Get there Affect Outcome and Safety? Lessons from Recent Studies (improve it and more)
Dov Gavish, Medicine A Wolfson, Sackler Faculty of Medicine Tel Aviv University, Israel

11:45 Combination Therapy in the Hypertensive Patient with Coronary Artery Disease
Paolo Palatini, Dept. of Medicine, Vascular Medicine, University of Padova, Italy

12:10 Conclusion

Poster Presentations

1. Risk of Obstructive Sleep Apnea among Patients with Type 2 Diabetes in Saudi Arabia
Metab Algeffari, Family Medicine Department, Qassim University College of Medicine, Saudi Arabia

2. A Fixed Combination of Lisinopril and Amlodipine in the Treatment of Overweight Patients with Arterial Hypertension and Coronary Heart Disease
Albert Galyavich, Dept. of Cardiology, Kazan State Medical University, Russia

3. Fixed Combination of Perindopril and Amlodipine: Optimization of Vascular Protection in Patients with Hypertension and Increased Pulse Wave Velocity
Sergey Nedogoda, Therapy and Endocrinology, Volgograd State Medical University, Russia

4. Combination Therapy in Treatment of Obesity and Metabolic Syndrome
Sergey Nedogoda, Therapy and Endocrinology, Volgograd State Medical University, Russia

5. Fixed Antihypertensive Combination Amlodipine/Indapamide Reduces Amlodipine-Induced Lower Leg Edema
Iana Simova, Dept. of Cardiology, National Multiprofile Transport Hospital Tsar Boris III, Bulgaria

6. Assessment of Quality of Life And Co Morbidity Resolution after Laparoscopic Sleeve Gastrectomy in Obese North Indian Population-A Prospective Single Institution Study
Amal Pushp Singh, General Surgery, Asian Institute of Medical Sciences, India
7. Combination of Lisinopril Hydrochlorothiazide and Amlodipine of Ukrainian Production Effectively Lowers Blood Pressure and Central Brachial
   **Olena Torbas**, Symptomatic Hypertension, FI NSC Institute of Cardiology n.a. M.D.Strazhesko, Ukraine

8. The Influence of Metabolic Factors on Central Blood Pressure Lowering Effect of Lisnopril or Bisoprolol Plus Hydrochlorothiazide and Amlodipine
   **Olena Torbas**, Symptomatic Hypertension, FI NSC Institute of Cardiology n.a. M.D.Strazhesko, Ukraine

9. Celecoxib FDCs for the treatment of Arthritis
   **Vuong Trieu**, R&D, Marina Biotech, USA

10. Add-on Empagliflozin Therapy (Alone or in Fixed Combination) Can Reduce the Risk of Cardiovascular Disease in People with TYPE 2 Diabetes
    **Katarina Vukelic**, Dept of Diabetes, Health Centre Grosuplje, Slovenia

11. The Association of Pediatric Obesity with Dyslipidemia, Type 2 Diabetes and Hypertension
    **Michael Yafi**, Dept. of Pediatrics, the University of Texas at Houston Health Science Center, USA

12. Effects of the Fixed Combination of Losartan and Hydrochlorothiazide on Blood Pressure in Hypertensive Patients with Diabetic Nephropathy
    **Gen Yasuda**, Dept. of Nephrology, Yokohama City University, Japan